Literature DB >> 32099630

The Split-Face Comparison of the Combined Er-YAG Laser and Hydroquinone 4% With Hydroquinone 4% Alone in the Treatment of Melasma in Iranian Patients: A Prospective, Interventional Case Study.

Nastaran Namazi1, Aida Hesami1, Yasaman Ketabi1.   

Abstract

Introduction: Melasma is one of the most common skin pigmentation disorders, which mostly affects the facial skin and has a considerable psychological impact on the patients. Melasma management has been one of the controversial issues in dermatology. We aimed to compare the combined treatment of the Er: YAG (erbium: yttrium-aluminum-garnet) laser plus hydroquinone (HQ) 4% with HQ 4% alone in the treatment of melasma.
Methods: Twenty-nine patients were treated with the combined Er: YAG laser and HQ 4% on one side of the face with HQ 4% alone on the other side. Three sessions of the laser rat 4-week intervals. The outcome was calculated using the Melasma Area Severity Index (MASI).
Results: The side that received the combined treatment (laser + HQ 4%) showed a statistically significant reduction in MASI compared to the side treated with HQ 4% alone.
Conclusion: Our study suggests the superiority of the combination of the Er: YAG laser and HQ 4% in the treatment of melasma compared to HQ 4% alone.
Copyright © 2020 J Lasers Med Sci.

Entities:  

Keywords:  Er: YAG laser; Hydroquinone; Melasma

Year:  2020        PMID: 32099630      PMCID: PMC7008736          DOI: 10.15171/jlms.2020.12

Source DB:  PubMed          Journal:  J Lasers Med Sci        ISSN: 2008-9783


  9 in total

1.  Clinical and histologic evaluation of six erbium:YAG lasers for cutaneous resurfacing.

Authors:  T S Alster
Journal:  Lasers Surg Med       Date:  1999       Impact factor: 4.025

2.  Erbium:YAG laser resurfacing for refractory melasma.

Authors:  R M Manaloto; T Alster
Journal:  Dermatol Surg       Date:  1999-02       Impact factor: 3.398

3.  Fast and effective skin ablation with an Er:YAG laser: determination of ablation rates and thermal damage zones.

Authors:  U Hohenleutner; S Hohenleutner; W Bäumler; M Landthaler
Journal:  Lasers Surg Med       Date:  1997       Impact factor: 4.025

4.  Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study.

Authors:  Enayat Attwa; Mohamed Khater; Magda Assaf; Manal Abdel Haleem
Journal:  Int J Dermatol       Date:  2014-09-30       Impact factor: 2.736

5.  Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women.

Authors:  A de A Tamega; L D B Miot; C Bonfietti; T C Gige; M E A Marques; H A Miot
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-01-03       Impact factor: 6.166

6.  Long-term results in low-fluence 1064-nm Q-Switched Nd:YAG laser for melasma: Is it effective?

Authors:  Hilal Gokalp; Ayse Deniz Akkaya; Yasemin Oram
Journal:  J Cosmet Dermatol       Date:  2016-06-28       Impact factor: 2.696

Review 7.  Melasma: a clinical and epidemiological review.

Authors:  Ana Carolina Handel; Luciane Donida Bartoli Miot; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

Review 8.  The use of ablative lasers in the treatment of facial melasma.

Authors:  Orlando Oliveira de Morais; Érica Freitas Lima Lemos; Márcia Carolline dos Santos Sousa; Ciro Martins Gomes; Izelda Maria Carvalho Costa; Carmen Déa Ribeiro de Paula
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

9.  Skin needling to enhance depigmenting serum penetration in the treatment of melasma.

Authors:  G Fabbrocini; V De Vita; N Fardella; F Pastore; M C Annunziata; M C Mauriello; A Monfrecola; N Cameli
Journal:  Plast Surg Int       Date:  2011-04-07
  9 in total
  1 in total

1.  A split-face comparison of fractional erbium: YAG laser plus Kligman's formula vs. Kligman's formula monotherapy for facial melasma.

Authors:  Maryam Nasimi; Maryam Ghiasi; Vahideh Lajevardi; Fatemeh Nasiri; Safoura Shakoei
Journal:  Arch Dermatol Res       Date:  2021-10-27       Impact factor: 3.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.